Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial

Andrew Morrow, Thomas J. Ford, Kenneth Mangion, Tushar Kotecha, Roby Rakhit, Gavin Galasko, Stephen P. Hoole, Anthony P. Davenport, Rajesh Kharbanda, Vanessa M. Ferreira, Mayooran Shanmuganathan, Amedeo Chiribiri, Divaka Perera, Haseeb Rahman, Jayanth R. Arnold, John P. Greenwood, Michael Fisher, Dirk Husmeier, N. A. Hill, Xiaoyu Luo, Nicola Williams, Laura Miller, Jill Dempster, Peter W. Macfarlane, Paul Welsh, Naveed Sattar, Andrew K. Whittaker, Alex Mc Connachie, Sandosh Padmanabhan, Colin BerryAmerican 2020 · DOI

Abstract

Microvascular angina is caused by cardiac small vessel disease, and dysregulation of the endothelin system is implicated. The minor G allele of the non-coding single nucleotide polymorphism (SNP) rs9349379 enhances expression of the endothelin 1 gene in human vascular cells, increasing circulating concentrations of ET-1. The prevalence of this allele is higher in patients with ischemic heart disease. Zibotentan is a potent, selective inhibitor of the ET<sub>A</sub> receptor. We have identified zibotentan as a potential disease-modifying therapy for patients with microvascular angina. METHODS: We will assess the efficacy and safety of adjunctive treatment with oral zibotentan (10 mg daily) in patients with microvascular angina and assess whether rs9349379 (minor G allele; population prevalence ~36%) acts as a theragnostic biomarker of the response to treatment with zibotentan. The PRIZE trial is a prospective, randomized, double-blind, placebo-controlled, sequential cross-over trial. The study population will be enriched to ensure a G-allele frequency of 50% for the rs9349379 SNP. The participants will receive a single-blind placebo run-in followed by treatment with either 10 mg of zibotentan daily for 12 weeks then placebo for 12 weeks, or vice versa, in random order. The primary outcome is treadmill exercise duration using the Bruce protocol. The primary analysis will assess the within-subject difference in exercise duration following treatment with zibotentan versus placebo. CONCLUSION: PRIZE invokes precision medicine in microvascular angina. Should our hypotheses be confirmed, this developmental trial will inform the rationale and design for undertaking a larger multicenter trial.
BibTeX
@inproceedings{morrow2020rationale,
  author = {Andrew Morrow and Thomas J. Ford and Kenneth Mangion and Tushar Kotecha and Roby Rakhit and Gavin Galasko and Stephen P. Hoole and Anthony P. Davenport and Rajesh Kharbanda and Vanessa M. Ferreira and Mayooran Shanmuganathan and Amedeo Chiribiri and Divaka Perera and Haseeb Rahman and Jayanth R. Arnold and John P. Greenwood and Michael Fisher and Dirk Husmeier and N. A. Hill and Xiaoyu Luo and Nicola Williams and Laura Miller and Jill Dempster and Peter W. Macfarlane and Paul Welsh and Naveed Sattar and Andrew K. Whittaker and Alex Mc Connachie and Sandosh Padmanabhan and Colin Berry},
  title = {{Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial}},
  booktitle = {American},
  year = {2020},
  doi = {10.1016/j.ahj.2020.07.007},
}

Loading related content...

Figure